EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Yamada, Teppei ^a,b   Azuma, Koichi ^a   Muta, Emi ^a   Kim, Jintaek ^a   Sugawara, Shunichi ^c   Zhang, Guang Lan ^d,e   Matsueda, Satoko ^a   Kasama Kawaguchi, Yuri ^a   Yamashita, Yuichi ^b   Yamashita, Takuto ^f   Nishio, Kazuto ^g   Itoh, Kyogo ^a   Hoshino, Tomoaki ^a   Sasada, Tetsuro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SENDAI KOUSEI HOSPITAL   (Japan)

^d Boston University Metropolitan College   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Kurume University Graduate School of Medicine Kurume University Graduate School of Medicine Graduate School Biostatistics   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; ERLOTINIB; GAMMA INTERFERON; GEFITINIB; HLA A ANTIGEN; LEUCYLISOLEUCYLMETHIONYLGLUTAMYLLEUCYLMETHIONYLPROLYLPHENYLALANINEGLYCYLCYSTYLLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHIONINE; METHIONYLGLUTAMYLLEUCYLMETHIONYLPROLYLPHENYLALANYLGLYCYLCYSTYLLEUCYLLEUCINE; THREONINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; MUTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; VERY ELDERLY;

AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84892396884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078389     Document Type: Article

References (49)

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382: 709-719.
2. Mitsudomi T, Suda K, Yatabe Y (2013) Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 10: 235-244.
3. Camidge DR, Doebele RC (2012) Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 9: 268-277.
4. Buettner R, Wolf J, Thomas RK (2013) Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 31: 1858-1865.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
6. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
9. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
10. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
11. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
13. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-smallcell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24-31.
14. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, et al. (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17: 5530-5537.
15. Ayoola A, Barochia A, Belani K, Belani CP (2012) Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer: an update. Cancer Invest 30: 433-446.
16. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
17. Finn OJ (2008) Cancer immunology. N Engl J Med 358: 2704-2715.
18. Schlom J (2012) Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 104: 599-613.
19. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
20. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, et al. (2010) Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 46: 1514-1519.
21. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
22. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, et al. (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 102: 16013-16018.
23. Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, et al. (2012) Exploiting the mutanome for tumor vaccination. Cancer Res 72: 1081-1091.
24. Heemskerk B, Kvistborg P, Schumacher TN (2012) The cancer antigenome. EMBO J 32: 194-203.
25. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
26. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, et al. (2011) Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 128: 1120-1128.
27. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, et al. (2008) Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57: 1413-1420.
28. Hogan KT, Eisinger DP, Cupp SB, Lekstrom KJ, Deacon DD, et al. (1998) The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 58: 5144-5150.
29. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, et al. (2001) A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 61: 4078-4083.
30. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, et al. (2001) High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61: 3718-3724.
31. Ichiki Y, Takenoyama M, Mizukami M, So T, Sugaya M, et al. (2004) Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 172: 4844-4850.
32. Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, et al. (2006) A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 118: 1992-1997.
33. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K (2005) Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 116: 36-44.
34. Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, et al. (2010) Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 101: 167-172.
35. Shichijo S, Hayashi A, Takamori S, Tsunosue R, Hoshino T, et al. (1995) Detection of MAGE-4 protein in lung cancers. Int J Cancer 64: 158-165.
36. Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, et al. (2008) Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci 99: 1656-1662.
37. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, et al. (2005) Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282.
38. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al. (2011) High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83: 8604-8610.
39. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V (2008) Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9: 8.
40. Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, et al. (2000) Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 164: 2565-2574.
41. Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, et al. (2004) Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 64: 2882-2888.
42. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, et al. (2001) Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62: 1200-1216.
43. Pogue RR, Eron J, Frelinger JA, Matsui M (1995) Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci U S A 92: 8166-8170.
44. Chen Y, Sidney J, Southwood S, Cox AL, Sakaguchi K, et al. (1994) Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol 152: 2874-2881.
45. Khan AR, Baker BM, Ghosh P, Biddison WE, Wiley DC (2000) The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J Immunol 164: 6398-6405.
46. La Rosa C, Krishnan R, Markel S, Schneck JP, Houghten R, et al. (2001) Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97: 1776-1786.
47. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, et al. (2011) Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. Vaccine 29: 3021-3030.
48. McKee MD, Roszkowski JJ, Nishimura MI (2005) T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 3: 35.
49. Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, et al. (1998) Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 8: 403-411.